Clinical Trial

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Name: A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC — clinical trial record (NCT06984718)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.

Trial Details

NCT Number	NCT06984718
Lead Sponsor	Akeso
Conditions	HCC, Hepatocellular Carcinoma
Enrollment	120 participants
Start Date	2025-06-25
Primary Completion	2026-11-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-05-22